About this trial
This study is a phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA
Patient Profile
Primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Waterford, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | SASCIA |
|---|---|
| Number: | 20-24 |
| Full Title: | Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA |
| Principal Investigator: | Prof. Patrick Morris |
|---|---|
| Type: | Collaborative |
| Sponsor: | GBG |
| Recruitment Started: |
Global: 28-Oct-2020 Ireland: 08-Dec-2021 |
| Global Recruitment Target: | Approx 1200 patients |
|---|---|
| Ireland Recruitment Target: | Approx 40 patients |